Noom

News

Noom Med app and accompanying GLP-1 implements

Noom expands its GLP-1 range with 'microdose' package

Noom is offering 'microdoses' of semaglutide at a knock-down price, claiming they can prevent side effects but remain effective for weight loss.

News

Noom offers cut-price compounded GLP-1 drug for obesity

Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk's obesity drug semaglutide to make the drug more accessible to consumers in the US.

News

Pulmonary fibrosis drug developer Avalyn files IPO

Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks